SCHEMBL21713614

SCHEMBL21713614

CC(C)(C)OC(=O)N1CCN(C(=O)O)CC1CNS(=O)(=O)c1cccnc1Cl

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
PARP1 P09874 2/20 0.39
KAT7 O95251 1/20 0.39
TGFBR1 P36897 3/20 0.39
NR1H2 P55055 3/20 0.38
NR1H3 Q13133 3/20 0.38
HPGD P15428 3/20 0.38
STS P08842 2/20 0.38
CHRM1 P11229 1/20 0.37
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
USP30 Q70CQ3 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21713417 0.89 PARP1 (0.53) POLBPARP1KAT7NR1H2NR1H3
SCHEMBL21713798 0.87 POLB (0.46) POLBTGFBR1HPGDSTSALDH1A1
SCHEMBL21714047 0.84 KDM1A (0.47) POLBHPGDSTSALDH1A1MAPT
SCHEMBL29819176 0.84 KDM1A (0.47) POLBHPGDSTSALDH1A1MAPT
SCHEMBL21713960 0.79 CNR2 (0.41) POLBTGFBR1HPGDSTSALDH1A1
SCHEMBL21713992 0.78 POLB (0.39) POLBTGFBR1HPGDSTSALDH1A1
SCHEMBL21713810 0.77 HPGD (0.42) POLBHPGDCHRM1ALDH1A1MAPT
SCHEMBL21714012 0.75 DPP4 (0.45) POLBHPGDALDH1A1MAPTTSHR
SCHEMBL21714141 0.74 HPGD (0.45) POLBHPGDALDH1A1MAPTTSHR
SCHEMBL21714153 0.73 POLB (0.53) POLBSTSOPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4364804-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica NV (BE) 2024-05-08 EP disclosed
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2024-02-13 US disclosed
EP-3833662-B1 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2024-01-17 EP disclosed
EP-3833662-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica N.V. (BE) 2021-06-16 EP disclosed
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2021-03-16 US disclosed
WO-2020041169-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-27 WO disclosed
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 POLB 2535/4885PARP1 2991/4885KAT7 2477/4885
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 POLB 2535/4885PARP1 2991/4885KAT7 2477/4885
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 POLB 2535/4885PARP1 2991/4885KAT7 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.